Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D W Morgan

Showing results (131-140 of 143) with videos related to

Pageof 15
Sort By:
Journal of Medicinal Chemistry|October 1, 1993
N-(carboxymethyl)-N-[3,5-bis(decyloxy)-phenyl]glycine (Ro 23-9358): a potent inhibitor of secretory phospholipases A2 with antiinflammatory activityR A LeMahieu, M Carson, R J Han, et al.
Agents and Actions|January 1, 1993
Interleukin-1 beta induces cytosolic PLA2 in parallel with prostaglandin E2 in rheumatoid synovial fibroblastsK I Hulkower, J W Coffey, W Levin, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|August 1, 1997
ABT-491, a highly potent and selective PAF antagonist, inhibits nasal vascular permeability associated with experimental allergic rhinitis in brown Norway ratsD H Albert, P Tapang, D W Morgan, et al.
European Journal of Applied Physiology and Occupational Physiology|January 1, 1996
Short-term changes in 10-km race pace aerobic demand and gait mechanics following a bout of high-intensity distance runningD W Morgan, H S Strohmeyer, J T Daniels, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|July 1, 1997
Ex vivo inhibition of beta-thromboglobulin release following administration to man of ABT-299, a novel prodrug of a potent platelet activating factor antagonistD H Albert, T J Magoc, S D Menacherry, et al.
Arthritis and Rheumatism|May 1, 1994
Interleukin-1 beta induces cytosolic phospholipase A2 and prostaglandin H synthase in rheumatoid synovial fibroblasts. Evidence for their roles in the production of prostaglandin E2K I Hulkower, S J Wertheimer, W Levin, et al.
European Journal of Pharmacology|April 23, 1997
Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonistD H Albert, T J Magoc, P Tapang, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 22, 1998
The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitisD H Albert, P E Malo, P Tapang, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitorsG S Sheppard, A S Florjancic, J R Giesler, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitorsD H Steinman, M L Curtin, R B Garland, et al.
Pageof 15

Showing results (131-140 of 143) with videos related to

Sort By:
Pageof 15
Journal of Medicinal Chemistry|October 1, 1993
N-(carboxymethyl)-N-[3,5-bis(decyloxy)-phenyl]glycine (Ro 23-9358): a potent inhibitor of secretory phospholipases A2 with antiinflammatory activityR A LeMahieu, M Carson, R J Han, et al.
Agents and Actions|January 1, 1993
Interleukin-1 beta induces cytosolic PLA2 in parallel with prostaglandin E2 in rheumatoid synovial fibroblastsK I Hulkower, J W Coffey, W Levin, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|August 1, 1997
ABT-491, a highly potent and selective PAF antagonist, inhibits nasal vascular permeability associated with experimental allergic rhinitis in brown Norway ratsD H Albert, P Tapang, D W Morgan, et al.
European Journal of Applied Physiology and Occupational Physiology|January 1, 1996
Short-term changes in 10-km race pace aerobic demand and gait mechanics following a bout of high-intensity distance runningD W Morgan, H S Strohmeyer, J T Daniels, et al.
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|July 1, 1997
Ex vivo inhibition of beta-thromboglobulin release following administration to man of ABT-299, a novel prodrug of a potent platelet activating factor antagonistD H Albert, T J Magoc, S D Menacherry, et al.
Arthritis and Rheumatism|May 1, 1994
Interleukin-1 beta induces cytosolic phospholipase A2 and prostaglandin H synthase in rheumatoid synovial fibroblasts. Evidence for their roles in the production of prostaglandin E2K I Hulkower, S J Wertheimer, W Levin, et al.
European Journal of Pharmacology|April 23, 1997
Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonistD H Albert, T J Magoc, P Tapang, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 22, 1998
The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitisD H Albert, P E Malo, P Tapang, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitorsG S Sheppard, A S Florjancic, J R Giesler, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitorsD H Steinman, M L Curtin, R B Garland, et al.
Pageof 15